We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Subacute cutaneous lupus erythematosus induced by PD‐1 Inhibitor therapy: two case reports and literature review.
- Authors
Diago, Adrian; Hueso, Luis; Ara‐Martín, Mariano; Abadías‐Granado, Isabel
- Abstract
Subacute cutaneous lupus erythematosus induced by PD-1 Inhibitor therapy: two case reports and literature review Immunotherapy was completely withdrawn in 6 of 10 cases, and some cases required the use of oral corticosteroids and/or treatment with systemic hiyroxychloroquine.3-5 Conversely, management of skin toxicities induced by immune checkpoint inhibitors rarely requires treatment interruption, and use of topical steroid, systemic antihistamines and/or topical moisturisers use to be enough.1 In conclusion, SCLE induced by PD-1 Inhibitor therapy is a rarely reported adverse effect, which can be persistent after immunotherapy discontinuation. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
- Subjects
LUPUS erythematosus; PROGRAMMED cell death 1 receptors; LITERATURE reviews; MELANOMA; IMMUNE checkpoint proteins
- Publication
Australasian Journal of Dermatology, 2021, Vol 62, Issue 2, pe347
- ISSN
0004-8380
- Publication type
Article
- DOI
10.1111/ajd.13538